TMP Share Price | Telemedycyna Polska SA Stock Analysis & Recommendation

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Compare Telemedycyna Polska SA with Similar Stocks

Genomed SA EMC Instytut Medyczny SA Centrum Medyczne Enel Med SA

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -42.13%, its profits have fallen by -44.5%

Consistent Underperformance against the benchmark over the last 3 years

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

PLN 8 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.25

Return on Equity

-143.91%

Price to Book

8.01

Revenue and Profits:

Net Sales:

1 Million

(Quarterly Results - Dec 2025)

Net Profit:

0 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

38.89%

6 Months

-4.58%

1 Year

-42.13%

2 Years

-55.36%

3 Years

-42.66%

4 Years

-45.18%

5 Years

-60.44%

Telemedycyna Polska SA for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

1.02%

EBIT Growth (5y)

-10.63%

EBIT to Interest (avg)

-1.49

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

0.11

Sales to Capital Employed (avg)

2.58

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

4.40%

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

-6.41

EV to EBIT

-3.62

EV to EBITDA

-4.30

EV to Capital Employed

6.75

EV to Sales

1.25

PEG Ratio

Dividend Yield

ROCE (Latest)

-186.57%

ROE (Latest)

Negative BV

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Bearish

RSI

Bearish

No Signal

Bollinger Bands

Mildly Bullish

Mildly Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Bullish

Bearish

Dow Theory

No Trend

Mildly Bearish

OBV

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is -7.14% vs 7.69% in Sep 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 25.00% vs 0.00% in Sep 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1.30",
          "val2": "1.40",
          "chgp": "-7.14%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.20",
          "val2": "-0.30",
          "chgp": "33.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.00",
          "val2": "-0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-0.30",
          "val2": "-0.40",
          "chgp": "25.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-182.00%",
          "val2": "-273.60%",
          "chgp": "9.16%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is -1.85% vs -11.48% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 44.44% vs -1,250.00% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "5.30",
          "val2": "5.40",
          "chgp": "-1.85%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-1.10",
          "val2": "-2.00",
          "chgp": "45.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.10",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.00",
          "val2": "-0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1.50",
          "val2": "-2.70",
          "chgp": "44.44%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-265.60%",
          "val2": "-415.40%",
          "chgp": "14.98%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ

Dec'25

Sep'25

Change(%)

Net Sales

1.30

1.40

-7.14%

Operating Profit (PBDIT) excl Other Income

-0.20

-0.30

33.33%

Interest

0.00

Exceptional Items

-0.00

Consolidate Net Profit

-0.30

-0.40

25.00%

Operating Profit Margin (Excl OI)

-182.00%

-273.60%

9.16%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Dec 2025 is -7.14% vs 7.69% in Sep 2025

Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is 25.00% vs 0.00% in Sep 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

5.30

5.40

-1.85%

Operating Profit (PBDIT) excl Other Income

-1.10

-2.00

45.00%

Interest

0.00

0.10

-100.00%

Exceptional Items

-0.00

Consolidate Net Profit

-1.50

-2.70

44.44%

Operating Profit Margin (Excl OI)

-265.60%

-415.40%

14.98%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is -1.85% vs -11.48% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 44.44% vs -1,250.00% in Dec 2024

All Annual Results

Company CV

About Telemedycyna Polska SA

Telemedycyna Polska SA

Pharmaceuticals & Biotechnology

Telemedycyna Polska SA is a Poland-based company engaged in provision of medical services via telephone, the Internet and radio waves. It operates Kardiotele system which enables cardiologic care and checks such as electrocardiogram (EKG) through telephone connection. Kariotele is addressed to individuals, as well as to nursing homes and rehabilitation centers. As of December 31, 2011, the Company operated one wholly owned subsidiary, Centrum Nadzoru Kardiologicznego Kardiofon Sp. z o.o.

Company Coordinates

Company Details

Ul. Ligocka 103 , KATOWICE None : 40-568

Tel: 48 32 3761455

http://www.telemedycynapolska.pl

Registrar Details